SV2017005515A - Formulaciones de polvo nasal para el tratamiento de la hipoglicemia - Google Patents

Formulaciones de polvo nasal para el tratamiento de la hipoglicemia

Info

Publication number
SV2017005515A
SV2017005515A SV2017005515A SV2017005515A SV2017005515A SV 2017005515 A SV2017005515 A SV 2017005515A SV 2017005515 A SV2017005515 A SV 2017005515A SV 2017005515 A SV2017005515 A SV 2017005515A SV 2017005515 A SV2017005515 A SV 2017005515A
Authority
SV
El Salvador
Prior art keywords
treatment
hypoglycemia
dust formulations
powder formulation
nasal
Prior art date
Application number
SV2017005515A
Other languages
English (en)
Inventor
Sankaram B Mantripragada
Claude A Piche
Betsbrugge Jo Jan Filip Van
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55538593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2017005515(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SV2017005515A publication Critical patent/SV2017005515A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0043—Non-destructive separation of the package, e.g. peeling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/07—General characteristics of the apparatus having air pumping means
    • A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/073—Syringe, piston type

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA FORMULACIÓN EN POLVO QUE CONTIENE GLUCAGÓN O UN ANÁLOGO DE GLUCAGÓN PARA ADMINISTRACIÓN NASAL, ÚTIL EN EL TRATAMIENTO DE HIPOGLICEMIA, Y EN PARTICULAR EL TRATAMIENTO DE HIPOGLICEMIA SEVERA. LA PRESENTE INVENCIÓN TAMBIÉN PROPORCIONA UN MÉTODO PARA ELABORAR ESTA FORMULACIÓN EN POLVO, Y A DISPOSITIVOS Y MÉTODOS PARA USAR LA FORMULACIÓN EN POLVO
SV2017005515A 2015-02-17 2017-08-14 Formulaciones de polvo nasal para el tratamiento de la hipoglicemia SV2017005515A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562117031P 2015-02-17 2015-02-17

Publications (1)

Publication Number Publication Date
SV2017005515A true SV2017005515A (es) 2018-08-27

Family

ID=55538593

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005515A SV2017005515A (es) 2015-02-17 2017-08-14 Formulaciones de polvo nasal para el tratamiento de la hipoglicemia

Country Status (41)

Country Link
US (3) US10213487B2 (es)
EP (3) EP3673900A1 (es)
JP (3) JP6522144B2 (es)
KR (1) KR102121443B1 (es)
CN (1) CN107278154B (es)
AU (2) AU2016220235B2 (es)
BR (1) BR112017014994B1 (es)
CA (1) CA2975562C (es)
CL (1) CL2017002031A1 (es)
CO (1) CO2017008148A2 (es)
CR (1) CR20170373A (es)
CY (1) CY1122716T1 (es)
DK (1) DK3258919T4 (es)
DO (1) DOP2017000179A (es)
EA (1) EA034820B1 (es)
EC (1) ECSP17053843A (es)
ES (1) ES2775498T5 (es)
FI (1) FI3258919T4 (es)
GT (1) GT201700179A (es)
HR (1) HRP20200222T4 (es)
HU (1) HUE049413T2 (es)
IL (1) IL253273B (es)
LT (1) LT3258919T (es)
MA (3) MA52253A (es)
MD (1) MD3258919T3 (es)
MX (1) MX2017010572A (es)
MY (1) MY175669A (es)
NZ (1) NZ734035A (es)
PE (1) PE20171334A1 (es)
PH (1) PH12017501486A1 (es)
PL (1) PL3258919T5 (es)
PT (1) PT3258919T (es)
RS (1) RS59918B2 (es)
SA (1) SA517382068B1 (es)
SG (1) SG11201705640PA (es)
SI (1) SI3258919T2 (es)
SV (1) SV2017005515A (es)
TN (1) TN2017000349A1 (es)
UA (1) UA121874C2 (es)
WO (1) WO2016133863A1 (es)
ZA (2) ZA201704944B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3258919T3 (ro) * 2015-02-17 2023-04-30 Lilly Co Eli Formulare de pulbere nazală pentru tratamentul hipoglicemiei
US11013873B2 (en) * 2017-01-06 2021-05-25 HealthPartners Institite Methods for treating patients with impaired awareness of hypoglycemia
AU2018319592B2 (en) 2017-08-20 2024-06-27 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
JP2020534333A (ja) 2017-09-21 2020-11-26 ザ スクリプス リサーチ インスティテュート 慢性副鼻腔炎を処置および防止するための新規治療
TWI771669B (zh) 2019-04-26 2022-07-21 美商美國禮來大藥廠 製備穩定胜肽調配物之方法
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
IL295977A (en) 2020-03-16 2022-10-01 Zealand Pharma As Liquid formulations of glucagon analogs
MX2022014216A (es) 2020-05-18 2022-12-07 Orexo Ab Nueva composicion farmaceutica para administracion de farmacos.
KR20240103005A (ko) 2021-11-25 2024-07-03 오렉쏘 에이비 아드레날린을 포함하는 약학적 조성물

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58189118A (ja) * 1982-04-30 1983-11-04 Takeda Chem Ind Ltd 経鼻投与製剤
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
US5059587A (en) 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
PT88490B (pt) * 1987-09-14 1992-11-30 Novo Nordisk As Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos
DK49791D0 (da) * 1991-03-20 1991-03-20 Novo Nordisk As Nasalt pulverpraeparat
DE19518810A1 (de) 1995-05-26 1996-11-28 Bayer Ag Nasal-Applikator
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
US6384016B1 (en) 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
EP1064102B1 (fr) 1998-03-10 2003-11-26 Valois S.A.S. Reservoir, procede de remplissage du reservoir et dispositif de distribution de la poudre contenue dans le reservoir
WO1999047160A1 (en) 1998-03-13 1999-09-23 Novo Nordisk A/S Stabilized aqueous peptide solutions
FR2817847B1 (fr) 2000-12-08 2003-03-28 Tebro Dispositif de distribution de produit fluide ou pulverulent
MXPA06003830A (es) 2003-10-09 2006-07-03 Bioactis Ltd Aparato para abastecer medicina pulverizada para la cavidad nasal.
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
JP2009518315A (ja) * 2005-12-02 2009-05-07 エムディーアールエヌエー，インコーポレイテッド グルコース調節ペプチドの上皮透過性を増大させるための製剤処方
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
EP2370460B1 (en) 2008-12-15 2014-04-30 Zealand Pharma A/S Glucagon analogues
MA32970B1 (fr) 2008-12-15 2012-01-02 Zealand Pharma As Analogues du glucagon
CA2747197A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
UA104766C2 (uk) 2009-07-13 2014-03-11 Зіленд Фарма А/С Ацильовані аналоги глюкагону
GB2472327B (en) 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
US9610329B2 (en) 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
JP2013523620A (ja) 2010-03-26 2013-06-17 ノヴォ ノルディスク アー／エス 新規のグルカゴンアナログ
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
CN103068841A (zh) 2010-06-24 2013-04-24 西兰制药公司 胰高血糖素类似物
KR20140114845A (ko) 2011-12-23 2014-09-29 질랜드 파마 에이/에스 글루카곤 유사체
EP3248642B1 (en) 2012-06-28 2020-04-08 The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services Nasal dry powder delivery system for vaccines and other treatment agents
FI124134B (en) 2012-07-02 2014-03-31 One Way Sport Oy Binding between a ski and a ski boot
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
MD3258919T3 (ro) * 2015-02-17 2023-04-30 Lilly Co Eli Formulare de pulbere nazală pentru tratamentul hipoglicemiei

Also Published As

Publication number Publication date
WO2016133863A1 (en) 2016-08-25
PL3258919T3 (pl) 2020-08-10
SI3258919T2 (sl) 2023-01-31
FI3258919T4 (fi) 2023-02-09
CA2975562A1 (en) 2016-08-25
GT201700179A (es) 2018-11-23
PE20171334A1 (es) 2017-09-13
EA201791560A1 (ru) 2018-02-28
PL3258919T5 (pl) 2023-02-27
DK3258919T3 (da) 2020-03-23
HRP20200222T4 (hr) 2022-12-23
EP3673899A1 (en) 2020-07-01
CN107278154A (zh) 2017-10-20
US20230302093A1 (en) 2023-09-28
MA41547B1 (fr) 2020-04-30
EA034820B1 (ru) 2020-03-25
SI3258919T1 (sl) 2020-03-31
JP2021107418A (ja) 2021-07-29
TN2017000349A1 (en) 2019-01-16
AU2021203035A1 (en) 2021-06-10
CR20170373A (es) 2017-09-18
BR112017014994A2 (pt) 2018-03-20
HUE049413T2 (hu) 2020-09-28
SA517382068B1 (ar) 2020-10-26
MD3258919T3 (ro) 2023-04-30
MY175669A (en) 2020-07-03
DK3258919T4 (da) 2022-11-21
UA121874C2 (uk) 2020-08-10
ES2775498T5 (es) 2023-01-31
EP3258919A1 (en) 2017-12-27
MA52252A (fr) 2021-02-17
BR112017014994B1 (pt) 2023-12-19
PH12017501486A1 (en) 2018-01-15
CN107278154B (zh) 2021-04-09
RS59918B2 (sr) 2023-01-31
US10213487B2 (en) 2019-02-26
AU2021203035B2 (en) 2023-07-13
JP2019147817A (ja) 2019-09-05
IL253273B (en) 2019-08-29
JP6522144B2 (ja) 2019-05-29
MD3258919T2 (ro) 2020-07-31
JP2018507852A (ja) 2018-03-22
JP7362687B2 (ja) 2023-10-17
SG11201705640PA (en) 2017-08-30
HRP20200222T1 (hr) 2020-05-29
NZ734035A (en) 2019-06-28
CO2017008148A2 (es) 2017-11-30
CL2017002031A1 (es) 2018-03-23
EP3258919B2 (en) 2022-11-09
ECSP17053843A (es) 2017-11-30
KR102121443B1 (ko) 2020-06-10
KR20170103934A (ko) 2017-09-13
PT3258919T (pt) 2020-03-26
CY1122716T1 (el) 2021-03-12
ZA201901241B (en) 2020-10-28
JP7094242B2 (ja) 2022-07-01
US20180000904A1 (en) 2018-01-04
DOP2017000179A (es) 2017-08-31
LT3258919T (lt) 2020-02-25
US20190282666A1 (en) 2019-09-19
IL253273A0 (en) 2017-08-31
ES2775498T3 (es) 2020-07-27
AU2016220235A1 (en) 2017-07-20
AU2016220235B2 (en) 2021-04-29
EP3258919B1 (en) 2020-01-15
CA2975562C (en) 2020-04-28
EP3673900A1 (en) 2020-07-01
MX2017010572A (es) 2017-12-07
ZA201704944B (en) 2021-05-26
MA52253A (fr) 2021-02-17
RS59918B1 (sr) 2020-03-31

Similar Documents

Publication Publication Date Title
SV2017005515A (es) Formulaciones de polvo nasal para el tratamiento de la hipoglicemia
CL2017003151A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
CL2016003075A1 (es) Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
CY1125205T1 (el) Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CR20170129A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico
EA201691911A1 (ru) Быстродействующие композиции инсулина
MX2016008978A (es) Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
GT201700124A (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2018000688A1 (es) Compuestos heterociclicos que contienen bencilamina y composiciones útiles contra infección por micobacterias
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
BR112017027721A2 (pt) formulação de alta concentração
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
HK1259373A1 (zh) 用於治療糖尿病的藥物製劑
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
CL2016003271A1 (es) Métodos para tratar infecciones
NZ725354A (en) Transdermal formulations of pergolide and uses thereof
CL2019001046A1 (es) Terapia de combinación que incluye un inhibidor mdm2 y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cáncer. (divisional solicitud 201601131)
EA201301341A1 (ru) Фармацевтическая композиция, обладающая панкреопротекторным действием, её применение для профилактики или лечения панкреатита и способ профилактики и лечения панкреатита
UY35956A (es) Formulación de atazanavir y cobicistat para el tratamiento del vih